Deep-dives, opinion, and science-led commentary on immuno-oncology, biomarkers, and precision medicine.
Why Precision Medicine Is Changing Cancer Treatment in 2026 Precision medicine and the Statue of Liberty may have more in…
IVD Companion Diagnostic Co-Development: How to Structure a Pharma-Diagnostics Partnership That Works If you work at the intersection of oncology…
ImmunoMark Summit Boston 2026: Everything You Need to Know If you work at the intersection of immuno-oncology and biomarker science,…
Multiplex Immunoassay Platforms: 2026 Comparison and Selection Guide You are standing at the platform selection crossroads again. MSD promises femtogram…
Sponsoring ImmunoMark Summit Boston: An ROI Guide for Diagnostics and Pharma Companies You have been here before. A promising conference,…
CAR-T Cell Therapy Biomarkers: Can We Finally Predict Who Will Respond? You have a patient. Relapsed, refractory, eligible for CAR-T.…
How to Validate an IO Biomarker in a Clinical Trial: Expert Guidance You have a promising IO biomarker. You have…
Boston Biotech & Life Sciences Events 2026: Your Complete Guide Boston has long been one of the world’s most important…
Tumor Mutational Burden: From Research to Clinical Reality Every few years, a biomarker arrives that genuinely changes how we think…
Speaker Spotlight Series: Pioneers Shaping IO Biomarker Science ImmunoMark Summit | UK Edition 2026 | London ImmunoMark Summit is the…
400+ senior leaders. Two streams. One agenda: advancing precision oncology.
